News and Updates

Discover how new FDA transparency standards, protocol-centric recruitment, and Medical Affairs integration are reshaping the future of clinical trials.

Serina Therapeutics completes sentinel dosing for SER-252 in its Phase Ib trial. Learn how this innovative polymer-drug conjugate aims to improve treatment.

GSK and Hansoh Pharma report success in a Chinese Phase III trial for a new SCLC antibody-drug conjugate, marking a major leap in targeted lung cancer care.

New Phase 1 trial results reveal a novel inhibitor targeting GNAQ and GNA11-mutant melanomas, marking a major step forward in precision cancer therapy.

Discover how mid-study CRO mergers create operational risks for clinical sites, from payment delays to staff turnover, and how to protect your trial data.

New clinical data confirms lecanemab’s subcutaneous autoinjector is bioequivalent to IV infusion, promising a simpler treatment path for Alzheimer’s patients.

Digital twins offer to revolutionize clinical trials, but regulatory validation challenges may hinder their progress. Explore the impact on medical research.

The FDA has raised clinical objections regarding image-reading protocols for the liver contrast agent Orviglance. Learn what this means for the drug's future.

Maharashtra FDA has banned two Cadila Pharmaceuticals drugs due to branding concerns. Learn how this regulatory move aims to prevent medication errors.

Longbio Pharma has received FDA clearance to begin clinical trials for LP-3, a potential new treatment targeting life-threatening peanut allergies.